<SECTION_HEADER>
Brand-Name vs Generic Drugs
</SECTION_HEADER>
<TEXT>
Theprimaryreasonforincreasingdrugspendingisthehighpriceof brandedproductsprotectedbymarketexclusivityprovisionsgranted bytheUSPatentandTrademarkOfficeandtheFoodandDrugAd- ministration (FDA) (Table 2). Although brand-name drugs com- priseonly10%ofalldispensedprescriptionsintheUnitedStates, theyaccountfor72%ofdrugspending.15 Between2008and2015, prices for the most commonly used brand-name drugs increased 164%,farinexcessoftheconsumerpriceindex(12%).16,17 Thean- nual cost of a growing number of “specialty drugs”—high-cost, ofteninjectablebiologicmedicationssuchaseculizumab(Soliris), pralatrexate (Folotyn), and elosulfase alfa (Vimizim)—exceeds $250000perpatient.
</TEXT>
<TABLE>
Table2.KeyTerminologyandExamplesofTherapeuticProducts
 Term           Definition                                      Examples
 Brand-name     Amedicationusuallysoldbytheoriginal             Nexium,
 drug           sponsoroftheapplicationforregulatory            Crestor,
                approval                                        Prilosec
 Generic        Aversionofabrand-namesmall-molecule             Omeprazole,
 drug           drugmanufacturedbyadifferentsupplier.           simvastatin
                Genericdrugscanbecertifiedasbioequivalent
                bytheFDAandsubstitutedforbrand-name
                drugsbyapharmacist.
 Biologic       Anoftenprotein-basedtherapeuticproduct          Filgrastim,
 drug           thatisdistinguishedbyitsmolecular               epoetinalfa
                complexity
 Specialty      Adrugdesignatedbyapayerforspecial               Sovaldi,
 drug           attention,oftenbecauseofitshighprice,but        Praluent,
                alsopotentiallybecauseoftheneedfor              Soliris
                distinctivehandlingorparticularpatient
                monitoring
Abbreviation:FDA,FoodandDrugAdministration.
</TABLE>
<TEXT>
Althoughbrand-namedrugsaccountforthegreatestincrease inprescriptiondrugexpenditures,anotherareathathascaptured theattentionofthepublicandofpolicymakershasbeenthesharp increase in the costs of some older generic drugs. In 2015, Turing Pharmaceuticals raised the price of pyrimethamine (Daraprim), a 63-year-oldtreatmentfortoxoplasmosis,by5500%,from$13.50 to$750apill.22 Thecompanywasabletosetthehighpricedespite theabsenceofanypatentprotectionbecausenoothercompeting manufacturerwaslicensedtomarketthedrugintheUnitedStates. Significantincreasesinthepricesofotherolderdrugsincludeiso- proterenol(2500%),nitroprusside(1700%),anddigoxin(637%). Even though the prices of most generic drug products have re- mained stable between 2008 and 2015, those of almost 400 (approximately2%ofthesampleinvestigated)increasedbymore than1000%.23
</TEXT>
<TEXT>
DrugpricesarehigherintheUnitedStatesthanintherestofthein- dustrialized world because, unlike that in nearly every other ad- vancednation,theUShealthcaresystemallowsmanufacturersto settheirownpriceforagivenproduct.11 Incontrast,incountrieswith nationalhealthinsurancesystems,adelegatedbodynegotiatesdrug pricesorrejectscoverageofproductsifthepricedemandedbythe manufacturerisexcessiveinlightofthebenefitprovided(Table3); manufacturersmaythendecidetoofferthedrugatalowerprice.24 InEnglandandWales,forexample,theNationalInstituteforHealth andCareExcellenceconsiderswhetheranewdrugpassesacost- utilitythreshold—usuallybetween£20000and£30000($25000- $40000)perquality-adjustedlife-yearadded—beforerecommend- ingitforcoveragebytheNationalHealthService.25 Althoughprices canvarywidelyaroundtheworld26 andhavealsoincreasedfaster than member states’ gross domestic products in recent years in Europe,27 USdrugpricespercapitastillsubstantiallyoutpacethose inothersettings.10 Drug companies’ ability to maintain high prices in the United Statesisbasedon2marketforces:protectionfromcompetitionand negotiatingpower.
</TEXT>
<TABLE>
Australia                                         Canada                          Germany                       UnitedKingdom
National        PharmaceuticalBenefits     PatentedMedicinesPrices       CanadianAgencyfor        FederalJointCommitteeor       NationalInstitutefor
organization    AdvisoryCommittee          ReviewBoard                   DrugsandTechnology       InstituteforQualityand        HealthandClinical
                                                                         inHealthcare             EfficiencyinHealthcare        Excellence
Remit           Publicpayers               Allpayers                     Publicpayersexcept       Allinsurers                   NationalHealthService
                                                                         inQuebec(noncancer
                                                                         drugs)
Review          Comparativeeffectiveness,  Therapeuticinnovation;        Comparative              Comparativebenefit            Clinicaleffectiveness
criteria        safety,and                 comparativepricingwith        effectiveness,safety,                                  andcost-effectiveness
                cost-effectiveness;        respecttoFrance,Germany,      andcost-effectiveness;
                projectedusageand          Italy,Sweden,United           patientexperiences
                overallcoststothehealth    Kingdom,andUnitedStates
                caresystem
Decision        Coverage(yes,no,limited)   Pricereductionsorrebates      Coverage                 Pricesettingafterfirstyear    Coverage
                                                                                                  onthemarket
Binding         Yes                        Yes                           No                       Yes                           Yes
</TABLE>
<PAGE_FOOTER>
jama.com
</PAGE_FOOTER>
<PAGE_HEADER>
ClinicalReview&Education SpecialCommunication
</PAGE_HEADER>
<PAGE_HEADER>
TheHighCostofPrescriptionDrugsintheUnitedStates
</PAGE_HEADER>
<UNSPECIFIED>
                                                                                      lions of individuals in the United States also now have high costs.
                                                                                      Forexample,manynewoncologydrugsenterthemarketataprice
                                                                                      exceeding$100000percourseoftherapy.20       Eventheaverageprice
                                                                                      ofinsulinhasincreased300%from2002to2013.21
                                                                                      Sources    of High   Drug   Prices  in the  United    States
                 Table3.ApproachestoDrugPricinginSelectedCountries
         860     JAMA   August23/30,2016  Volume316,Number8   (Reprinted)
                                                    Copyright Copyright 2016 2016 American American Medical Medical Association. Association. All All rights rights reserved. reserved.
Downloaded   From:  http://jama.jamanetwork.com/   by a University of Florida User on 09/13/2016
</UNSPECIFIED>
<PAGE_BREAK>
